<DOC>
	<DOC>NCT00134199</DOC>
	<brief_summary>To evaluate the effect of 6-month administration of CP-945,598 on: - weight loss and waist circumference, - blood pressure, cholesterol, glucose - other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-Î± and hsCRP - the relationship between the concentration of the drug on the blood and the above parameters - physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression</brief_summary>
	<brief_title>A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Male and/or female subjects without clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12 lead ECG and clinical laboratory tests Body Mass Index (BMI) Â³30 and &lt;40 kg/m2, for subjects with no additional co morbidities; BMI Â³27 kg/m2 and &lt;40 kg/m2, for subjects with co morbidities [history of essential hypertension and/or dyslipidemia defined as high LDL (Â³160 mg/dL) or high total cholesterol (Â³240 mg/dL)]; Subjects with resting sitting systolic blood pressure of 140 mmHg or greater or diastolic blood pressure of 90 mmHg or greater. Subjects with type 2 diabetes or fasting blood glucose concentration Â³126 mg/dL; Subjects with a history of eating disorders like anorexia nervosa or bulimia nervosa Subjects on prescription and nonprescription appetite or weight modifying drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>